|
Pneumocystis (carinii)
jiroveci
Read the Chapter
Sliding Table of
Contents on the left of the screen
Tables and Figures
Table 1: Reasons for Failure to Improve with PCP Therapy
Vignettes
Hawksworth DL.
Responsibility in naming pathogens: the case of
Pneumocystis jirovecii, the causal agent of pneumocystis pneumonia.
Lancet Infect Dis. 2007 Jan;7:3-5; discussion 5.
Huang L,
Morris A,
Limper AH,
Beck JM;
ATS Pneumocystis
Workshop Participants.
An
Official ATS Workshop Summary: Recent advances and future directions in
pneumocystis pneumonia (PCP). Proc Am
Thorac Soc. 2006;3(8):655-64.
Skelly MJ, et al.
S-Adenosylmethionine levels in the Diagnosis of
Pneumocystis carinii Pneumonia in Patients with HIV Infection.
Clin Infect Dis 2008;46(3):467-471.
Walzer PD et al.
Early Predictors of Mortality from Pneumocystis jirovecii
Pneumonia in HIV-infected Patients: 1985-2006. Clin Infect
Dis. 2008 Feb 15;46(4):625-33.
Choukri
F,
Menotti J,
Sarfati C,
Lucet JC,
Nevez G,
Garin YJ,
Derouin F,
Totet A.
Spread of Pneumocystis jirovecii in the surrounding
air of patients with Pneumocystis pneumonia. Clin Infect Dis.
2010 Aug 1;51(3):259-65.
Review Article:
Adhikari P, Mietzner T. Cell Mediated Immunity. 2008.
Morris A et al. Is There Anything New in Pneumocystis jirovecii
Pneumonia? Changes in P. jirovecii Pneumonia Over the Course of the
AIDS Epidemic. Clin Infect Dis 2008;46:634-636.
Authors
M. Patricia George, M.D., 
Matthew Gingo, M.D.,
Alison Morris, M.D.
|
www.antimicrobe.org